MedPath

System-IGF-1 Pathway and Alzheimer's Disease

Completed
Conditions
Alzheimer's Disease
Mild Cognitive Impairment
Control With Normal Activities of Daily Living
Cognitive Function 1, Social
Registration Number
NCT00647478
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Brief Summary

The aim is to assess the relationship between levels of IGF-I system components and cognitive status in patients with Alzheimer's disease (AD), in elderly subjects with normal cognitive function, and in patients with mild cognitive impairment (MCI).

Detailed Description

AD is the most common cause of dementia. During aging, decline of biological brain functions due to a number of genetic and environmental factors facilitates the onset of AD. MCI includes prodromal AD.

The identification of the risk factors for AD must be a priority in order to define the best therapeutic approach.

Recent data support the notion that IGF-I pathway accounts for neuronal protection, with a dual effect, on both brain Aβ peptide and tau protein.

This large, multicenter, prospective, observational, cross-sectional population-based study in 3 parallel groups (200 participants per group) is aimed to assess differences between IGF-I and IGFBP3 circulating levels and polymorphisms in AD patients and control elderly subjects, and in MCI patients.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
693
Inclusion Criteria

Caucasian patients after a comprehensive geriatric assessment and giving informed written consent.

  • In each arm :
  1. elderly subjects with normal cognitive function,
  2. patients with dementia of AD type (DSM-IV and NINCDS-ADRDA criteria),
  3. patients with MCI (European Consortium on Alzheimer's Disease, EADC).
Read More
Exclusion Criteria

Non AD dementia Major depression Use of anticholinesterase agent All diseases or major sensory deficits or any condition that might interfere with cognitive assessment and study objectives

Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Circulating IGF-I and IGFBP-3 levels in AD patients and control elderly subjects at the time of assessment(T0).24 hours
Secondary Outcome Measures
NameTimeMethod
Circulating IGF-I and IGFBP-3 levels24 hours
Genetic polymorphisms in IGF-I / IGFBP-324 hours
Circulating IGF-I and IGFBP-3 levels and genetic polymorphisms in IGF-I / IGFBP-3 according to cognitive function.24 hours

Trial Locations

Locations (1)

Broca Hospital Memory Clinic (CMRR)

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath